Cardio Diagnostics Holdings, Inc. (CDIO) Stock Price & Analysis
Cardio Diagnostics Holdings, Inc. (CDIO) fell 4.90% to USD 1.55 as of July 25, 2026 at 05:04 UTC, according to Nexqual real-time market data.
CDIO last closed at USD 1.63; the session ranged USD 1.52–1.64 on volume of 1,201,047 shares. Market capitalization is $4.59M, with a 52-week range of USD 0.97–7.91 (NCM). Source: Nexqual, July 25, 2026 at 05:04 UTC.
Key Statistics (as of July 25, 2026 at 05:04 UTC)
| Price | USD 1.55 |
|---|---|
| Change | ▼ 4.90% (down) |
| Previous Close | USD 1.63 |
| Open | USD 1.63 |
| Day Range | USD 1.52 – 1.64 |
| 52-Week Range | USD 0.97 – 7.91 |
| Volume | 1,201,047 shares |
| Market Cap | $4.59M |
| Exchange | NCM |
Technical Analysis (CDIO)
Nexqual's technical model rates CDIO "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 05:04 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.67 (oversold) |
| vs SMA50 | Below (USD 1.86) |
| MACD | -0.09 (negative) |
Analyst Ratings (CDIO)
Wall Street analysts rate CDIO "None", per Nexqual as of July 25, 2026 at 05:04 UTC.
| Consensus Rating | None |
|---|
Earnings (CDIO)
| Next Earnings Date | 2026-08-13 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-03-31 | USD -0.97 vs est -1.8 ▲ beat |
| 2024-12-31 | USD -0.3 vs est -1.8 ▲ beat |
| 2024-09-30 | USD -1.8 vs est -1.5 ▼ miss |
| 2024-06-30 | USD -1.8 vs est -2.7 ▲ beat |
Source: Nexqual, July 25, 2026 at 05:04 UTC.
Financials & Fundamentals (CDIO)
| Total Revenue | $16,565 |
|---|---|
| Revenue Growth (YoY) | +185.10% |
| Gross Margin | +100.00% |
| Operating Margin | -66598.40% |
| Profit Margin | +0.00% |
| ROE | -65.59% |
| Debt / Equity | 5.99 |
| Current Ratio | 15.76 |
| Total Cash | $7.08M |
| Total Debt | $533,002 |
| Free Cash Flow | $-3.93M |
Source: Nexqual, July 25, 2026 at 05:04 UTC.
Financial Health Score (CDIO)
Nexqual rates Cardio Diagnostics Holdings, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 05:04 UTC.
| Growth | Strong — Revenue +104% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $7M cash, no debt |
| Cash Flow | Weak — FCF negative: -$4M, burning cash |
| Efficiency | Critical — ROE -66%, ROA -38.0% |
Ownership (CDIO)
| Insider Ownership | +8.31% |
|---|---|
| Institutional Ownership | +9.34% |
| Shares Outstanding | 2.96M |
| Float | 2.83M |
| Short % of Float | +0.15% |
Source: Nexqual, July 25, 2026 at 05:04 UTC.
Leadership (CDIO)
Cardio Diagnostics Holdings, Inc. is led by Meeshanthini V. Dogan (age 36), Co-Founder, CEO & Director, per Nexqual as of July 25, 2026 at 05:04 UTC.
| Co-Founder, CEO & Director | Meeshanthini V. Dogan (age 36) |
|---|---|
| CFO & Principal Accounting Officer | Elisa Michael Luqman Esq. (age 61) |
| Chief Technology Officer | Timur Dogan (age 36) |
| Co-Founder, Chief Medical Officer & Director | Robert A. Philibert (age 63) |
Major Backers & Investors (CDIO)
Notable institutional backers of Cardio Diagnostics Holdings, Inc. include Jane Street Group, LLC, HRT Financial LP, Fidelity, according to Nexqual as of July 25, 2026 at 05:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jane Street Group, LLC | 2.75% |
| HRT Financial LP | 2.11% |
| Fidelity | 0.77% |
| Renaissance Technologies | 0.52% |
| Scientech Research LLC | 0.47% |
| UBS Group AG | 0.34% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.49% |
| BlackRock | 1.17% |
| Geode Capital | 1.09% |
Source: Nexqual, July 25, 2026 at 05:04 UTC.
From Cardio Diagnostics Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
- The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management.
- It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform.
- It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SPRC | SciSparc Ltd. | USD 5.33 | ▲ 10.12% |
| PXMD | PaxMedica, Inc. | USD 0 | ▲ 0% |
| FRGT | Freight Technologies, Inc. | USD 3.01 | ▼ 15.45% |
| INBS | Intelligent Bio Solutions Inc. | USD 1.75 | ▼ 2.78% |
| HSCS | HeartSciences Inc. | USD 2.39 | ▼ 4.4% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:04 UTC. This page is informational and not investment advice.